Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376279 | 1.00 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL4375251 | 0.91 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4375246 | 0.91 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6322416 | 0.89 | ADORA2A (0.62) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6322425 | 0.89 | ADORA2A (0.62) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL9056149 | 0.88 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL4371461 | 0.87 | ADORA2A (0.64) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4371473 | 0.87 | ADORA2A (0.64) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10688350 | 0.86 | ADORA2A (0.72) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL7176166 | 0.85 | ADORA2A (0.73) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-7094769-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2006-06-08 | — | — | US | disclosed |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | ADORA2A 9/4885ADORA3 23/4885ADORA1 40/4885 |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | ADORA2A 10/4885ADORA3 23/4885ADORA1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.